Literature DB >> 25931274

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

W Wang1, J E Cortes2, P Lin1, J D Khoury1, D Ai1, Z Tang1, G Tang1, J L Jorgensen1, L J Medeiros1, S Hu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25931274     DOI： 10.1038/leu.2015.96

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Authors:  Alice Fabarius; Armin Leitner; Andreas Hochhaus; Martin C Müller; Benjamin Hanfstein; Claudia Haferlach; Gudrun Göhring; Brigitte Schlegelberger; Martine Jotterand; Andreas Reiter; Susanne Jung-Munkwitz; Ulrike Proetel; Juliana Schwaab; Wolf-Karsten Hofmann; Jörg Schubert; Hermann Einsele; Anthony D Ho; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Michael Lauseker; Markus Pfirrmann; Joerg Hasford; Susanne Saussele; Rüdiger Hehlmann
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

2.  Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.

Authors:  Guido Marcucci; Clara D Bloomfield; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Stefano Volinia; Ann-Kathrin Eisfeld; Michael D Radmacher; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jason H Mendler; Yue-Zhong Wu; Deedra Nicolet; Peter Paschka; Bayard L Powell; Thomas H Carter; Meir Wetzler; Jonathan E Kolitz; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard M Stone
Journal:  Leukemia       Date:  2014-03-21       Impact factor: 11.528

Review 3.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

4.  Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.

Authors:  Eric Lippert; Gabriel Etienne; Marie-Joelle Mozziconacci; Sophy Laibe; Carine Gervais; Stéphane Girault; Nathalie Gachard; Isabelle Tigaud; Nicole Dastugue; François Huguet; Marie-Pierre Fort; Laurence Legros; Virginie Eclache; Francois-Xavier Mahon
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

5.  Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population.

Authors:  Qitian Mu; Qiuling Ma; Yungui Wang; Zhimei Chen; Xiangmin Tong; Fei-Fei Chen; Ying Lu; Jie Jin
Journal:  Ann Hematol       Date:  2012-02-15       Impact factor: 3.673

6.  How I treat CML blast crisis.

Authors:  Rüdiger Hehlmann
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

7.  Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Authors:  Simona Luatti; Fausto Castagnetti; Giulia Marzocchi; Carmen Baldazzi; Gabriele Gugliotta; Ilaria Iacobucci; Giorgina Specchia; Lucia Zanatta; Giovanna Rege-Cambrin; Rege Cambrin; Marco Mancini; Elisabetta Abruzzese; Alfonso Zaccaria; Maria Grazia Grimoldi; Alessandro Gozzetti; Gaia Ameli; Maria Adele Capucci; Giandomenico Palka; Paolo Bernasconi; Francesca Palandri; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani; Nicoletta Testoni
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

8.  Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

Authors:  Jorge E Cortes; Moshe Talpaz; Francis Giles; Susan O'Brien; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Stefan Faderl; Deborah A Thomas; William Wierda; Allessandra Ferrajoli; Sima Jeha; Hagop M Kantarjian
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

9.  Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.

Authors:  Dushyant Verma; Hagop Kantarjian; Jianqin Shan; Susan O'Brien; Zeev Estrov; Guillermo Garcia-Manero; Charles Koller; Gautam Borthakur; Jorge Cortes
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  12 in total

1.  Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.

Authors:  Zimu Gong; L Jeffrey Medeiros; Jorge E Cortes; Zi Chen; Lan Zheng; Yan Li; Shi Bai; Pei Lin; Roberto N Miranda; Jeffrey L Jorgensen; Timothy J McDonnell; Wei Wang; Hagop M Kantarjian; Shimin Hu
Journal:  Blood Adv       Date:  2017-12-08

2.  Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.

Authors:  Alireza Salem; Sanam Loghavi; Guilin Tang; Yang O Huh; Elias J Jabbour; Hagop Kantarjian; Wei Wang; Shimin Hu; Rajyalakshmi Luthra; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Am J Hematol       Date:  2017-04-06       Impact factor: 10.047

Review 3.  Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication.

Authors:  Nur Hezrin Shahrin; Carol Wadham; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

4.  Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.

Authors:  Wei Wang; Jorge E Cortes; Pei Lin; Michael W Beaty; Di Ai; Hesham M Amin; Timothy J McDonnell; Chi Young Ok; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2015-08-04       Impact factor: 22.113

5.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Wei Wang; Jorge E Cortes; Guilin Tang; Joseph D Khoury; Sa Wang; Carlos E Bueso-Ramos; Joseph A DiGiuseppe; Zi Chen; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu
Journal:  Blood       Date:  2016-03-22       Impact factor: 22.113

6.  Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Authors:  Michele Baccarani; Elisabetta Abruzzese; Vincenzo Accurso; Francesco Albano; Mario Annunziata; Sara Barulli; Germana Beltrami; Micaela Bergamaschi; Gianni Binotto; Monica Bocchia; Giovanni Caocci; Isabella Capodanno; Francesco Cavazzini; Michele Cedrone; Marco Cerrano; Monica Crugnola; Mariella D'Adda; Chiara Elena; Carmen Fava; Paola Fazi; Claudio Fozza; Sara Galimberti; Valentina Giai; Antonella Gozzini; Gabriele Gugliotta; Alessandra Iurlo; Gaetano La Barba; Luciano Levato; Alessandro Lucchesi; Luigia Luciano; Francesca Lunghi; Monia Lunghi; Michele Malagola; Roberto Marasca; Bruno Martino; Angela Melpignano; Maria Cristina Miggiano; Enrico Montefusco; Caterina Musolino; Fausto Palmieri; Patrizia Pregno; Davide Rapezzi; Giovanna Rege-Cambrin; Serena Rupoli; Marzia Salvucci; Rosaria Sancetta; Simona Sica; Raffaele Spadano; Fabio Stagno; Mario Tiribelli; Simona Tomassetti; Elena Trabacchi; Massimiliano Bonifacio; Massimo Breccia; Fausto Castagnetti; Fabrizio Pane; Domenico Russo; Giuseppe Saglio; Simona Soverini; Paolo Vigneri; Gianantonio Rosti
Journal:  Blood Adv       Date:  2019-12-23

7.  Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Z Chen; W Wang; J E Cortes; E Liu; R N Miranda; C Zhao; J Yuan; X Lu; W Yang; M D Ameri; H M Kantarjian; L J Medeiros; S Hu
Journal:  Blood Cancer J       Date:  2016-05-06       Impact factor: 11.037

8.  Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.

Authors:  W Wang; Z Chen; Z Hu; C C Yin; S Li; S Bai; C E Bueso-Ramos; L J Medeiros; S Hu
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

9.  Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.

Authors:  Cheng-Cheng Ma; Ye Chai; Hui Ling Chen; Xin Wang; Ying Gao; Wan Li Hu; Xue Xiang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

10.  Cytogenetic alterations in CML: not all created equal.

Authors:  Zimu Gong; Wei Wang; Shimin Hu
Journal:  Oncotarget       Date:  2018-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.